Open AccessLenalidomide in relapsed refractory non-Hodgkin′s lymphoma: An Indian perspective
Author(s) -
K C Lakshmaiah,
Kirty Shetty,
Vishwanath Sathyanarayanan,
Lokanatha Dasappa,
Linu Jacob Abraham,
K Govinda Babu
Publication year - 2015
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.151418
Subject(s) - lenalidomide , medicine , mantle cell lymphoma , lymphoma , gastroenterology , refractory (planetary science) , follicular lymphoma , oncology , thalidomide , surgery , multiple myeloma , physics , astrobiology
Lenalidomide an immunomodulatory agent has shown activity in relapsed/refractory lymphoma. This study was conducted to evaluate its efficacy and optimal dose in Indian patients with relapsed/refractory lymphoma who were unable or unwilling to undergo autologous hematopoietic stem cell transplant.